Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide once weekly added to basal insulin glargine in type 2 diabetes
2014-003502-33Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2014
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Exenatide once weekly + titrated basal insulin glargine with Placebo + titrated basal insulin glargine (2 arms). Primary endpoint: Change in HbA1c from baseline to Week 28. Started Nov 2014; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2014-003502-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003502-33.